Compare Hut 8 Corp (HUT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Tango Therapeutics Inc. — how do they compare? Hut 8 Corp trades at $71.49 (market cap $9.23B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Hut 8 Corp is far larger — about 2.5× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 12 Days and Tango Therapeutics Inc. for 0 Days on average.
| HUT | TNGX | |
|---|---|---|
Market Cap | $9.23B | $3.74B |
Volume | 12,843,584 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $133.02 | $32.90 |
52-Week Low | $33.76 | $7.50 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $16.67B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $83.61, down 1.91% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth projections but faces significant profitability challenges with a -188.59% net income margin. Recent developments include securing a $1.07 billion credit facility and positive analyst coverage with 94% buy ratings and a $163.62 consensus price target.
While analyst sentiment remains overwhelmingly positive, HUT faces substantial execution risks with consecutive earnings misses and negative cash flow from operations. The stock offers significant upside potential based on analyst targets but requires careful monitoring of profitability improvements and AI infrastructure contract execution.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
